Chairman’s Message

As we navigate through a dynamic See more..

Nasser Al Madi

CEO Message

Born from the heart of Najd See more..

Fahad Bushaqer


logo
Chairman’s Message

As we navigate through a dynamic economic landscape, I wish to extend my heartfelt gratitude for See more..

Nasser Al Madi

 

logo
CEO Message

Born from the heart of Najd, we embodies the local values with international best practices See more..

Fahad Bushaqer

Private Equity (PE) Funds

To deliver superior returns for our stakeholders via strategic approach, disciplined strategies and systematic execution

team-details__thumb

At National Capital, the alternative investments team are capable and focused in managing alternative investments funds in the Saudi market, delivering institutional-grade investment operations, rigorous regulatory compliance, and value-driven portfolio growth. By leveraging our deep sector expertise and strategic insight, we identify high-impact investment opportunities across emerging and transformative industries. Our focus is on maximizing long-term returns while effectively managing risk, aligning our success with that of our stakeholders.

 

 

National Capital Manufacturing Fund (I)

MKKN is a Saudi based regulated company – Authorized by GAMI – in the military and defense sector. MKKN is a leader in developing and manufacturing medium and large caliber artillery and air delivered munitions, following NATO (STANAG/MIL) standards. MKKN is equipped with a state-of-the-art production facility based in Riyadh; including forging, automated welding, numerical control machining, and metallurgical labs; delivering precision, reliability, and quality end products.

Fund Executive Summary Terms
  • Capital: SAR 64.9 M (at inception)
  • Valuation: SAR 104 M (Dec 2024)
  • Tenor: 5 years (+ 1 + 1 year)
  • Target IRR: 15%
  • RVPI: 1.87 (Dec 2024)
  • NAV: SAR 16,367 (Dec 2024)

 

 

National Capital Healthcare Technology & AI Fund

Founded in 2021, ALPHAIOTA is a Saudi based pioneer in applying global AI innovation to local Saudi market challenges with focus on healthcare sector. Backed by a team of seasoned tech and medical professionals, ALPHAIOTA is transforming diagnostics, automating patient workflows, and driving value across the Kingdom’s health ecosystem. Its partnerships and product launches align with Saudi Vision 2030’s digital health goals.

Fund Terms
  • Capital: SAR 60 M – raised 24 M
  • Tenor: 5 years (+ 1 + 1 year)
  • Target IRR: 15%
Fund Strategy

The fund seeks income and long-term growth by acquiring 85% of Alphaiota and transforming it into a holding company focused on medical device integration, genetic profiling, and AI-driven health technology.

Related Links